Published in Arch Gen Psychiatry on September 01, 1978
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull (2006) 1.09
Management of the schizophrenic patient. Can Med Assoc J (1979) 1.09
Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations. Eur Arch Psychiatry Clin Neurosci (2005) 1.00
Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) (2003) 0.98
Co-occurring depressive symptoms in the older patient with schizophrenia. Drugs Aging (2008) 0.96
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ (1990) 0.93
Managing suicide risk in patients with schizophrenia. CNS Drugs (2011) 0.92
The relationships between depression and remission in first-episode psychosis. World Psychiatry (2006) 0.90
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ (1989) 0.90
Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich. Eur Arch Psychiatry Clin Neurosci (1990) 0.88
Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci (2005) 0.86
Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci (2005) 0.84
The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues Clin Neurosci (2006) 0.82
Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatry Neurosci (2001) 0.81
Does self-perceived mood predict more variance in cognitive performance than clinician-rated symptoms in schizophrenia? Schizophr Bull (2006) 0.81
Suicidal behavior in the older patient with schizophrenia. Aging health (2011) 0.78
Psychosocial correlates with depressive symptoms six years after a first episode of psychosis as compared with findings from a general population sample. BMC Psychiatry (2004) 0.78
Negative symptoms: psychopathological models. J Psychiatry Neurosci (1991) 0.77
[New insights into the pathogenesis and pathophysiology of depression]. Nervenarzt (2007) 0.76
Assessment of anti-psychotic drugs. Br J Clin Pharmacol (1981) 0.75
Who should receive clozapine? Arch Gen Psychiatry (1988) 1.49
Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response. Br J Psychiatry (1991) 1.42
Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry (1974) 1.38
Protein-decorated micelle structure of sodium-dodecyl-sulfate--protein complexes as determined by neutron scattering. Eur J Biochem (1990) 1.24
Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry (1984) 1.22
The many faces of akathisia. Compr Psychiatry (1975) 1.15
Hyperacetylation of core histones does not cause unfolding of nucleosomes. Neutron scatter data accords with disc shape of the nucleosome. J Biol Chem (1986) 1.12
The solution structure of functionally active human proliferating cell nuclear antigen determined by small-angle neutron scattering. J Mol Biol (1998) 1.12
Characterization of the antibody response to acetone-killed typhoid vaccine. Public Health Rep (1967) 1.09
Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry (1978) 1.08
Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry (1976) 1.05
Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry (1987) 1.05
Subjective response to antipsychotic drugs. Arch Gen Psychiatry (1981) 1.04
Shape and compactness of the isolated ribosomal 16 S RNA and its complexes with ribosomal proteins. J Mol Biol (1983) 1.03
Spatial arrangement of DNA-dependent RNA polymerase of Escherichia coli and DNA in the specific complex. A neutron small angle scattering study. J Mol Biol (1988) 1.03
Phenothiazine-induced decompensation. Arch Gen Psychiatry (1974) 1.01
Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry (1987) 0.95
Importance of akinesia: plasma chlorpromazine and prolactin levels. Am J Psychiatry (1980) 0.95
Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry (1992) 0.95
A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry (1983) 0.94
Conformational rearrangements of an archaeal chaperonin upon ATPase cycling. Curr Biol (2000) 0.93
Shape determinations of ribosomal proteins in situ. Proc Natl Acad Sci U S A (1983) 0.91
Difficulties in differentiating amebic from pyogenic liver abscess. Arch Intern Med (1967) 0.91
Solution structure of a short DNA fragment studied by neutron scattering. Eur J Biochem (1986) 0.90
Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis (1976) 0.90
Architecture of bacterial lipid A in solution. A neutron small-angle scattering study. Eur J Biochem (1990) 0.87
Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry (1984) 0.86
Structure of dodecyl sulfate-protein complexes at subsaturating concentrations of free detergent. Biophys Chem (1994) 0.85
ATP-induced structural change of the thermosome is temperature-dependent. J Struct Biol (2001) 0.85
Towards a structural characterization of charge-driven polymer micelles. Eur Phys J E Soft Matter (2009) 0.85
The quaternary structure of Tet repressors bound to the Tn10-encoded tet gene control region determined by neutron solution scattering. EMBO J (1989) 0.85
Drug refusal in schizophrenia: causes and prescribing hints. Hosp Community Psychiatry (1978) 0.85
Schizophrenia. Psychiatr Clin North Am (1993) 0.85
Spatial arrangement of sigma-factor and core enzyme of Escherichia coli RNA polymerase. A neutron solution scattering study. J Mol Biol (1991) 0.84
Salt-dependent compaction of di- and trinucleosomes studied by small-angle neutron scattering. Biophys J (2000) 0.84
Deuterium incorporation into Escherichia coli proteins. A neutron-scattering study of DNA-dependent RNA polymerase. Eur J Biochem (1986) 0.83
On the pH-dependence of the reaction of hemoglobin with carbon monoxide. Eur J Biochem (1975) 0.83
Structural changes of the Escherichia coli GroEL-GroES chaperonins upon complex formation in solution: a neutron small angle scattering study. J Struct Biol (1998) 0.82
Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. Psychopharmacol Bull (1989) 0.82
Predicting outcome of antipsychotic drug treatment from early response. Am J Psychiatry (1980) 0.81
Psychotic patients' understanding of informed consent. Am J Psychiatry (1985) 0.81
Translocation makes the ribosome less compact. J Mol Biol (1987) 0.81
Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry (1980) 0.81
Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. J Pharm Sci (1993) 0.81
Plasma levels of haloperidol and clinical response. Psychopharmacol Bull (1985) 0.80
Neutron scattering study of the binding of tRNAPhe to Escherichia coli phenylalanyl-tRNA synthetase. Biochemistry (1983) 0.80
Plasma haloperidol levels: clinical response and fancy mathematics. Arch Gen Psychiatry (1985) 0.80
The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. Psychopharmacology (Berl) (1987) 0.79
Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay. Ther Drug Monit (1990) 0.79
Milieu therapy: contraindications? Arch Gen Psychiatry (1973) 0.79
Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry (1994) 0.79
Clinical perspectives of some neuroleptics through development and application of their assays. Ther Drug Monit (1993) 0.79
Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol (1990) 0.79
The domain structure of tryptophan synthase. A neutron scattering study. Eur J Biochem (1985) 0.79
Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population. Arch Gen Psychiatry (1990) 0.79
Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol (1989) 0.79
Phenothiazine-induced stress incontinence. J Urol (1973) 0.79
Plasma levels of chlorpromazine in schizophrenia; a critical review of the literature. Arch Gen Psychiatry (1978) 0.78
Akathisia with haloperidol and thiothixene. Psychopharmacol Bull (1984) 0.78
Variable dose studies provide misleading therapeutic windows. J Clin Psychopharmacol (1986) 0.78
Mapping proteins of the 50S subunit from Escherichia coli ribosomes. Biochim Biophys Acta (2001) 0.78
Fluphenazine plasma levels and clinical response. Psychopharmacol Bull (1990) 0.78
Kappa-casein micelles: structure, interaction and gelling studied by small-angle neutron scattering. Eur J Biochem (1991) 0.77
Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J Chromatogr B Biomed Appl (1994) 0.77
Therapeutic monitoring of chlorpromazine I: Pitfalls in plasma analysis. Ther Drug Monit (1985) 0.77
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci (1994) 0.77
Why do patients with manic-depressive illness stop their lithium? Compr Psychiatry (1975) 0.77
Traumatic neuroses in Vietnam returnees. A forgotten diagnosis? Arch Gen Psychiatry (1973) 0.77
Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res (1984) 0.77
Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharmacol Bull (1988) 0.77
Neutron-scattering studies of accurately reconstituted nucleosome core particles and the effect of ionic strength on core particle structure. Eur J Biochem (1983) 0.77
Lithium in treatment failures. J Nerv Ment Dis (1975) 0.77
Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry (1984) 0.77
Lithium in previous treatment failures. Curr Psychiatr Ther (1976) 0.76
Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Arch Gen Psychiatry (1994) 0.76
Drug treatment of schizophrenia. Overview of recent research. Schizophr Res (1991) 0.76
Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine. Ther Drug Monit (1994) 0.75
Test dose response in schizophrenia: chlorpromazine blood and saliva levels. Arch Gen Psychiatry (1978) 0.75
Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology (Berl) (1989) 0.75
Early prediction of relapse in schizophrenia: an application of receiver operating characteristic (ROC) methods. Psychopharmacol Bull (1991) 0.75
Dialysis for schizophrenia: review of clinical trials and implications for further research. Am J Psychiatry (1980) 0.75
Low-dose treatment strategies. J Clin Psychiatry (1986) 0.75
Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry (1981) 0.75
Toward a more reliable diagnosis of akathisia. Arch Gen Psychiatry (1986) 0.75
Plasma homovanillic acid as a predictor of response to fluphenazine treatment. Psychopharmacol Bull (1989) 0.75
Propranolol as a primary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry (1988) 0.75
The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharmacol Bull (1987) 0.75
Anticholinergic effects on memory: benztropine vs. amantadine. Psychopharmacol Bull (1987) 0.75
The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. J Clin Psychopharmacol (1987) 0.75
A preliminary attempt to relate individual differences in EEG test dose response to clinical effect. Biol Psychiatry (1982) 0.75
The neuroleptic malignant syndrome manifested as a prolonged confusional state. J Clin Psychopharmacol (1988) 0.75
Consent and liability with neuroleptics: the problem of tardive dyskinesia. Int J Law Psychiatry (1986) 0.75
Information processing and maintenance dose requirements in schizophrenia. Psychopharmacol Bull (1988) 0.75
Does a plasma level of chlorpromazine help? Psychol Med (1981) 0.75
Structural elements of the 50 S subunit of E. coli ribosomes. Basic Life Sci (1984) 0.75
Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology (Berl) (1986) 0.75
Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities. Arch Gen Psychiatry (1988) 0.75
Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate. Psychopharmacol Bull (1986) 0.75
Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. Compr Psychiatry (1981) 0.75
Micrographia and akinesia. Am J Psychiatry (1979) 0.75